These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 25525183)

  • 1. The usefulness of dynamic O-(2-18F-fluoroethyl)-L-tyrosine PET in the clinical evaluation of brain tumors in children and adolescents.
    Dunkl V; Cleff C; Stoffels G; Judov N; Sarikaya-Seiwert S; Law I; Bøgeskov L; Nysom K; Andersen SB; Steiger HJ; Fink GR; Reifenberger G; Shah NJ; Coenen HH; Langen KJ; Galldiks N
    J Nucl Med; 2015 Jan; 56(1):88-92. PubMed ID: 25525183
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of O-(2-(18)F-fluoroethyl)-L-tyrosine PET for differentiation of local recurrent brain metastasis from radiation necrosis.
    Galldiks N; Stoffels G; Filss CP; Piroth MD; Sabel M; Ruge MI; Herzog H; Shah NJ; Fink GR; Coenen HH; Langen KJ
    J Nucl Med; 2012 Sep; 53(9):1367-74. PubMed ID: 22872742
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnostic performance of 18F-FET PET in newly diagnosed cerebral lesions suggestive of glioma.
    Rapp M; Heinzel A; Galldiks N; Stoffels G; Felsberg J; Ewelt C; Sabel M; Steiger HJ; Reifenberger G; Beez T; Coenen HH; Floeth FW; Langen KJ
    J Nucl Med; 2013 Feb; 54(2):229-35. PubMed ID: 23232275
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The diagnostic accuracy of detecting malignant transformation of low-grade glioma using O-(2-[18F]fluoroethyl)-l-tyrosine positron emission tomography: a retrospective study.
    Bashir A; Brennum J; Broholm H; Law I
    J Neurosurg; 2018 Apr; 130(2):451-464. PubMed ID: 29624154
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of O-(2-18F-fluoroethyl)-L-tyrosine PET as a diagnostic tool for detection of malignant progression in patients with low-grade glioma.
    Galldiks N; Stoffels G; Ruge MI; Rapp M; Sabel M; Reifenberger G; Erdem Z; Shah NJ; Fink GR; Coenen HH; Langen KJ
    J Nucl Med; 2013 Dec; 54(12):2046-54. PubMed ID: 24159047
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The use of dynamic O-(2-18F-fluoroethyl)-l-tyrosine PET in the diagnosis of patients with progressive and recurrent glioma.
    Galldiks N; Stoffels G; Filss C; Rapp M; Blau T; Tscherpel C; Ceccon G; Dunkl V; Weinzierl M; Stoffel M; Sabel M; Fink GR; Shah NJ; Langen KJ
    Neuro Oncol; 2015 Sep; 17(9):1293-300. PubMed ID: 26008606
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of 18F-FET PET for grading of recurrent gliomas: is evaluation of uptake kinetics superior to standard methods?
    Pöpperl G; Kreth FW; Herms J; Koch W; Mehrkens JH; Gildehaus FJ; Kretzschmar HA; Tonn JC; Tatsch K
    J Nucl Med; 2006 Mar; 47(3):393-403. PubMed ID: 16513607
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dynamic O-(2-18F-fluoroethyl)-L-tyrosine positron emission tomography differentiates brain metastasis recurrence from radiation injury after radiotherapy.
    Ceccon G; Lohmann P; Stoffels G; Judov N; Filss CP; Rapp M; Bauer E; Hamisch C; Ruge MI; Kocher M; Kuchelmeister K; Sellhaus B; Sabel M; Fink GR; Shah NJ; Langen KJ; Galldiks N
    Neuro Oncol; 2017 Feb; 19(2):281-288. PubMed ID: 27471107
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An interindividual comparison of O-(2-[18F]fluoroethyl)-L-tyrosine (FET)- and L-[methyl-11C]methionine (MET)-PET in patients with brain gliomas and metastases.
    Grosu AL; Astner ST; Riedel E; Nieder C; Wiedenmann N; Heinemann F; Schwaiger M; Molls M; Wester HJ; Weber WA
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):1049-58. PubMed ID: 21570201
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serial 18F-FET PET Imaging of Primarily 18F-FET-Negative Glioma: Does It Make Sense?
    Unterrainer M; Schweisthal F; Suchorska B; Wenter V; Schmid-Tannwald C; Fendler WP; Schüller U; Bartenstein P; Tonn JC; Albert NL
    J Nucl Med; 2016 Aug; 57(8):1177-82. PubMed ID: 27033893
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of O-(2-18F-fluoroethyl)-L-tyrosine PET and 3-123I-iodo-alpha-methyl-L-tyrosine SPECT in brain tumors.
    Pauleit D; Floeth F; Tellmann L; Hamacher K; Hautzel H; Müller HW; Coenen HH; Langen KJ
    J Nucl Med; 2004 Mar; 45(3):374-81. PubMed ID: 15001676
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Suspected recurrence of brain metastases after focused high dose radiotherapy: can [
    Romagna A; Unterrainer M; Schmid-Tannwald C; Brendel M; Tonn JC; Nachbichler SB; Muacevic A; Bartenstein P; Kreth FW; Albert NL
    Radiat Oncol; 2016 Oct; 11(1):139. PubMed ID: 27769279
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of treatment response in patients with glioblastoma using O-(2-18F-fluoroethyl)-L-tyrosine PET in comparison to MRI.
    Galldiks N; Langen KJ; Holy R; Pinkawa M; Stoffels G; Nolte KW; Kaiser HJ; Filss CP; Fink GR; Coenen HH; Eble MJ; Piroth MD
    J Nucl Med; 2012 Jul; 53(7):1048-57. PubMed ID: 22645298
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic Value of O-(2-[18F]-Fluoroethyl)-L-Tyrosine-Positron Emission Tomography Imaging for Histopathologic Characteristics and Progression-Free Survival in Patients with Low-Grade Glioma.
    Bette S; Gempt J; Delbridge C; Kirschke JS; Schlegel J; Foerster S; Huber T; Pyka T; Zimmer C; Meyer B; Ringel F
    World Neurosurg; 2016 May; 89():230-9. PubMed ID: 26855307
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Response assessment of bevacizumab in patients with recurrent malignant glioma using [18F]Fluoroethyl-L-tyrosine PET in comparison to MRI.
    Galldiks N; Rapp M; Stoffels G; Fink GR; Shah NJ; Coenen HH; Sabel M; Langen KJ
    Eur J Nucl Med Mol Imaging; 2013 Jan; 40(1):22-33. PubMed ID: 23053325
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of 18F-FET PET and perfusion-weighted MR imaging: a PET/MR imaging hybrid study in patients with brain tumors.
    Filss CP; Galldiks N; Stoffels G; Sabel M; Wittsack HJ; Turowski B; Antoch G; Zhang K; Fink GR; Coenen HH; Shah NJ; Herzog H; Langen KJ
    J Nucl Med; 2014 Apr; 55(4):540-5. PubMed ID: 24578243
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The use of O-(2-18F-fluoroethyl)-L-tyrosine PET in the diagnosis of gliomas located in the brainstem and spinal cord.
    Tscherpel C; Dunkl V; Ceccon G; Stoffels G; Judov N; Rapp M; Meyer PT; Kops ER; Ermert J; Fink GR; Shah NJ; Langen KJ; Galldiks N
    Neuro Oncol; 2017 May; 19(5):710-718. PubMed ID: 28039366
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic value of 18F-fluoroethyl-L-tyrosine PET and MRI in small nonspecific incidental brain lesions.
    Floeth FW; Sabel M; Stoffels G; Pauleit D; Hamacher K; Steiger HJ; Langen KJ
    J Nucl Med; 2008 May; 49(5):730-7. PubMed ID: 18413396
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early Postoperative
    Marner L; Nysom K; Sehested A; Borgwardt L; Mathiasen R; Henriksen OM; Lundemann M; Munck Af Rosenschöld P; Thomsen C; Bøgeskov L; Skjøth-Rasmussen J; Juhler M; Kruse A; Broholm H; Scheie D; Lauritsen T; Forman JL; Wehner PS; Højgaard L; Law I
    J Nucl Med; 2019 Aug; 60(8):1053-1058. PubMed ID: 30683767
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Flare Phenomenon in
    Filss CP; Schmitz AK; Stoffels G; Stegmayr C; Lohmann P; Werner JM; Sabel M; Rapp M; Goldbrunner R; Neumaier B; Mottaghy FM; Shah NJ; Fink GR; Galldiks N; Langen KJ
    J Nucl Med; 2020 Sep; 61(9):1294-1299. PubMed ID: 32005771
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.